Ioduro (123i) De Sodio Curium Pharma Spain

Sodium Iodide, the active ingredient in Ioduro (123i) De Sodio Curium Pharma Spain, is a radiopharmaceutical presented as a sterile solution for intravenous use. It is employed in nuclear medicine to visualize thyroid tissue and to assist in the assessment of thyroid‑related disorders. GNH USA supplies Ioduro (123i) De Sodio Curium Pharma Spain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and nuclear medicine centres worldwide.

Ioduro (123i) De Sodio is used in nuclear medicine for imaging and diagnostic assessment of thyroid and related conditions. - Thyroid imaging: enables visualization of thyroid tissue distribution for diagnostic purposes. - Thyroid cancer staging: assists in detecting metastatic disease and evaluating disease extent. - Radioiodine therapy planning: helps determine the appropriate therapeutic dose by assessing iodine uptake.

Adverse reactions may occur following intravenous administration of Sodium Iodide (123 I).

Common Side Effects: - Nausea: mild and transient. - Headache: typically low‑intensity. - Transient flushing: brief sensation of warmth. - Injection site discomfort: mild pain or irritation at the site of administration.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or anaphylaxis in susceptible individuals. - Radiation‑induced thyroiditis: inflammation of the thyroid gland after exposure. - Severe hypotension: marked drop in blood pressure requiring medical attention.

When using Sodium Iodide (123 I), certain precautions should be observed to ensure patient safety. - Pregnancy: avoid unless the diagnostic benefit outweighs potential fetal risk. - Breastfeeding: discontinue or avoid unless essential, as radioiodine can be secreted in milk. - Renal impairment: monitor renal function because the agent is cleared renally. - Thyroid dysfunction: assess baseline thyroid status before administration. - Concurrent radioactive iodine therapy: avoid overlapping procedures that could interfere with imaging results. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Sodium Iodide (123 I) may interact with other agents that affect iodine handling or imaging quality.

Major Interactions (Avoid): - Other radiopharmaceuticals: simultaneous use can compromise image interpretation. - Iodine‑containing contrast agents: may block thyroid uptake and reduce diagnostic accuracy. - Thyroid hormone suppressive therapy: can alter iodine distribution and affect results.

Moderate Interactions (Monitor Closely): - Diuretics: may modify renal clearance of the agent. - Antithyroid drugs (e.g., methimazole): can reduce uptake in thyroid tissue. - Beta‑blockers: may influence hemodynamic response during injection.